title: Human fasciolosis: a study on the relation of infection intensity and treatment to hepatobiliary affection.
abstract: Seventeen patients with established fasciolosis and ten normal controls were enrolled in the study. The Fasciola patients were divided according to infection intensity into two groups (four patients with high intensity and thirteen patients with low intensity) as assessed by egg counts coupled with ultrasonography for detection of worms in the biliary system. Aspartate and alanine aminotransferases (AST and ALT) levels were similar to those of the controls, within the accepted normal limits, before and after treatment denoting absence of hepatocellular injury. Total serum bile acids, individual bile acids: cholic acid (CA) and chenodeoxycholic acid (CDCA), gamma glutamyl transpeptidase (GGT) and serum alkaline phosphatase (SAP) were significantly higher among all patients as compared to the controls denoting a degree of cholestatic lesion in those patients. Patients with high infection intensity revealed higher parameters than those with low intensity. The difference was not significant. One month after treatment, there was a significant improvement in the cholestasis indicating parameters in all Fasciola cases compared to the pretreatment ones. This indicates the effective role of the drug on the hepatobiliary function. However, the levels were still different from the controls. In Fasciola infection, total and individual serum bile acids in conjunction with GGT and SAP evaluate the hepatobiliary status and detect any minor abnormalities especially in anicteric subjects. Studied after treatment, they can be useful indices for assessment of the improvement.
authors.affiliation: Department of Parasitology, Alexandria University, Egypt.
authors.forename: M M
authors.initials: MM
authors.lastname: Osman
authors.forename: Y
authors.initials: Y
authors.lastname: Ismail
authors.forename: T Y
authors.initials: TY
authors.lastname: Aref
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000097:blood; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002648:Child; D005209:Fasciola / Q000302:isolation & purification; D005211:Fascioliasis / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D005260:Female; D006801:Humans; D008099:Liver / Q000201:enzymology; D008109:Liver Diseases, Parasitic / Q000188:drug therapy*; D008297:Male; D000077682:Triclabendazole
chemical_list: D000871:Anthelmintics; D001562:Benzimidazoles; D001647:Bile Acids and Salts; D000077682:Triclabendazole